Risk Factors Update Summary
- Reported net losses decreased from $148.1 million in 2022 to $135.4 million in 2023.
- Cash, cash equivalents, and short-term investments decreased from approximately $490 million to $363 million.
- Number of full-time employees increased from approximately 87 in 2022 to 163 in 2023.
- Manufacturing activities paused until June 2024 due to deficiencies identified in EU readiness audit.
- Potential competition from GLP-1 agonists may impact growth and addressable market for products.
- Difficulty enrolling patients in clinical trials may continue to affect costs and outcomes.
- Changes in privacy laws may impact business operations and financial condition.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=1850270&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.